Humacyte Inc (NASDAQ:HUMA) — Market Cap & Net Worth
Market Cap & Net Worth: Humacyte Inc (HUMA)
Humacyte Inc (NASDAQ:HUMA) has a market capitalization of $144.98 Million ($144.98 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17715 globally and #4133 in its home market, demonstrating a 2.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Humacyte Inc's stock price $0.65 by its total outstanding shares 222019108 (222.02 Million). Review HUMA total debt and obligations to assess the company's total debt and financial obligations.
Humacyte Inc Market Cap History: 2020 to 2026
Humacyte Inc's market capitalization history from 2020 to 2026. Data shows change from $2.26 Billion to $144.98 Million (-37.86% CAGR).
Index Memberships
Humacyte Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.01% | #494 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1737 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.01% | #235 of 263 |
Weight: Humacyte Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Humacyte Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Humacyte Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
104.64x
Humacyte Inc's market cap is 104.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.26 Billion | $1.49 Million | -$66.52 Million | 1514.38x | N/A |
| 2021 | $1.61 Billion | $1.26 Million | -$26.48 Million | 1274.46x | N/A |
| 2022 | $468.46 Million | $1.56 Million | -$11.96 Million | 299.34x | N/A |
| 2025 | $213.25 Million | $2.04 Million | -$40.83 Million | 104.64x | N/A |
Competitor Companies of HUMA by Market Capitalization
Companies near Humacyte Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Humacyte Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Humacyte Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Humacyte Inc's market cap moved from $2.26 Billion to $ 144.98 Million, with a yearly change of -37.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $144.98 Million | -32.01% |
| 2025 | $213.25 Million | -80.98% |
| 2024 | $1.12 Billion | +77.82% |
| 2023 | $630.53 Million | +34.60% |
| 2022 | $468.46 Million | -70.90% |
| 2021 | $1.61 Billion | -28.71% |
| 2020 | $2.26 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Humacyte Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $144.98 Million USD |
| MoneyControl | $144.98 Million USD |
| MarketWatch | $144.98 Million USD |
| marketcap.company | $144.98 Million USD |
| Reuters | $144.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to b… Read more